Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.

Okonkwo OC, Alosco ML, Jerskey BA, Sweet LH, Ott BR, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 Sep;6(5):404-11. doi: 10.1016/j.jalz.2010.02.003.

2.

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.

Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS; Alzheimer's Disease Cooperative Study.

Alzheimers Dement. 2010 Sep;6(5):412-9. doi: 10.1016/j.jalz.2009.12.003.

3.

Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment.

Wang PN, Liu HC, Lirng JF, Lin KN, Wu ZA.

Psychiatry Res. 2009 Mar 31;171(3):221-31. doi: 10.1016/j.pscychresns.2008.05.002. Epub 2009 Feb 13.

PMID:
19217759
4.

Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.

Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Ballard C, Greig NH.

Pharmacogenet Genomics. 2008 Apr;18(4):289-98. doi: 10.1097/FPC.0b013e3282f63f29.

PMID:
18334913
5.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC.

Neurology. 2004 Feb 24;62(4):591-600.

6.

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.

7.

Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.

Hochstetler H, Trzepacz PT, Wang S, Yu P, Case M, Henley DB, Degenhardt E, Leoutsakos JM, Lyketsos CG.

J Alzheimers Dis. 2016;50(1):271-82. doi: 10.3233/JAD-150563.

8.

Semantic memory activation in amnestic mild cognitive impairment.

Woodard JL, Seidenberg M, Nielson KA, Antuono P, Guidotti L, Durgerian S, Zhang Q, Lancaster M, Hantke N, Butts A, Rao SM.

Brain. 2009 Aug;132(Pt 8):2068-78. doi: 10.1093/brain/awp157. Epub 2009 Jun 10.

9.

Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA, Harvey DJ, Jack CR Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2010 Aug;31(8):1401-18. doi: 10.1016/j.neurobiolaging.2010.04.029.

10.

Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.

Kerr DS, Stella F, Radanovic M, Aprahamian I, Bertollucci PH, Forlenza OV.

Bipolar Disord. 2016 Feb;18(1):71-7. doi: 10.1111/bdi.12367. Epub 2016 Feb 15.

PMID:
26877211
11.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
12.

Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8. Epub 2010 Jun 30.

13.

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P.

Mol Psychiatry. 2015 Nov;20(11):1322-8. doi: 10.1038/mp.2014.123. Epub 2014 Oct 7.

14.

The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.

Löwe LC, Gaser C, Franke K; Alzheimer’s Disease Neuroimaging Initiative.

PLoS One. 2016 Jul 13;11(7):e0157514. doi: 10.1371/journal.pone.0157514. eCollection 2016.

15.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264
16.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

17.

Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes.

He J, Farias S, Martinez O, Reed B, Mungas D, Decarli C.

Arch Neurol. 2009 Nov;66(11):1393-9. doi: 10.1001/archneurol.2009.252.

18.

Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease.

Brown PJ, Devanand DP, Liu X, Caccappolo E; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Jun;68(6):617-26. doi: 10.1001/archgenpsychiatry.2011.57.

19.

Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.

Bangen KJ, Clark AL, Werhane M, Edmonds EC, Nation DA, Evangelista N, Libon DJ, Bondi MW, Delano-Wood L; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016 Mar 29;52(3):849-61. doi: 10.3233/JAD-150900.

20.

Effect of mild cognitive impairment and APOE genotype on resting cerebral blood flow and its association with cognition.

Wierenga CE, Dev SI, Shin DD, Clark LR, Bangen KJ, Jak AJ, Rissman RA, Liu TT, Salmon DP, Bondi MW.

J Cereb Blood Flow Metab. 2012 Aug;32(8):1589-99. doi: 10.1038/jcbfm.2012.58. Epub 2012 May 2.

Supplemental Content

Support Center